Related Experiment Video

Updated: Sep 3, 2025

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

13.5K

Inhibition of PTPN21 has antitumor effects in glioma by restraining the EGFR/PI3K/AKT pathway

Xiao-Qiang Li1, Bo-Chuan Liu1, Xiao-Bing Jiang1

  • 1Department of Neurosurgery, Second Affiliated Hospital of Xi'an Medical University, No. 167 Fangdong Street, Baqiao District, Xi'an 710038, China.

Toxicology and Applied Pharmacology
|July 30, 2022
PubMed

Insights

Protein tyrosine phosphatase non-receptor type 21 (PTPN21) is elevated in glioma, promoting tumor growth. Silencing PTPN21 inhibits glioma progression by targeting the EGFR/PI3K/AKT pathway, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Protein tyrosine phosphatase non-receptor type 21 (PTPN21) is implicated in various cancers.
  • The role of PTPN21 in glioma, a primary brain tumor, is not well understood.

Purpose of the Study:

  • To investigate the relevance and function of PTPN21 in glioma.
  • To elucidate the underlying molecular mechanisms of PTPN21 in glioma progression.

Main Methods:

  • Analysis of The Cancer Genome Atlas (TCGA) data for PTPN21 expression in glioma.
  • Validation of PTPN21 levels in clinical glioma specimens.
  • In vitro and in vivo experiments involving PTPN21 silencing in glioma cells.
  • Investigation of the epidermal growth factor receptor (EGFR)/phosphatidyl-inositole-3 kinase (PI3K)/AKT signaling pathway.

Main Results:

  • PTPN21 is significantly upregulated in glioma tissues.
  • High PTPN21 expression correlates with poor survival rates in glioma patients.
  • PTPN21 silencing demonstrated potent anticancer effects, including reduced proliferation, cell cycle arrest, suppressed metastasis, and enhanced chemosensitivity.
  • PTPN21 promotes glioma via the EGFR/PI3K/AKT pathway; EGFR inhibition or AKT reactivation counteracted PTPN21's effects.
  • Tumorigenic potential was significantly reduced in PTPN21-silenced glioma cells in vivo.

Conclusions:

  • PTPN21 is a key oncogenic driver in glioma.
  • Targeting PTPN21, particularly through the EGFR/PI3K/AKT pathway, presents a promising therapeutic strategy for glioma treatment.
Keywords:
AKTEGFRGliomaPI3KPTPN21

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.9K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K